Quantcast

Latest Antibody-drug conjugate Stories

2014-08-21 23:16:22

Gallus BioPharmaceuticals, LLC, a premier, full service biopharmaceutical contract development and manufacturing organization announced today that it has been selected by Progenics Pharmaceuticals, Inc., an oncology company focused on the development of innovative approaches to targeting and treating cancer, to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics’ PSMA ADC product candidate. St. Louis, MO (PRWEB) August 21, 2014 Gallus...

2014-07-08 04:21:35

OXFORD, England and SAN JOSE, California, July 8, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research...

2014-06-24 23:03:33

Redwood Bioscience and Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the results of an in vivo toxicology study, demonstrating that an Antibody Drug Conjugate (ADC) generated using the proprietary SMARTag™ platform has a better toxicity profile than a conventional ADC. Somerset, N.J. (PRWEB) June 24, 2014 Redwood Bioscience and Catalent Pharma...

2014-06-24 08:30:07

- Collaboration and license agreement allows Merck Serono to expand its oncology drug portfolio ROCKLAND, Mass., June 24, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Mersana Therapeutics, Inc., Cambridge, Mass., U.S., announced today an agreement to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody part specifically targets and...

2014-06-20 08:23:51

CORAL SPRINGS, Florida, June 20, 2014 /PRNewswire/ -- Healthcare industry update: companies develop advanced technologies and approaches for cancer treatment, clinical data reveals progress: GenSpera, Inc. (OTC: GNSZ), Seattle Genetics, Inc. (NASDAQ: SGEN), OXiGENE, Inc. (NASDAQ: OXGN), Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK) and StemCells Inc. (NASDAQ: STEM) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of...

2014-06-18 04:21:18

OXFORD, England and SAN JOSE, California, June 18, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Dr Keith E Wilson as Chief Scientific Officer. Dr Wilson joins from AbbVie where he was the company's Global Leader for Antibody Drug Conjugates. Dr Keith E Wilson brings to Oxford BioTherapeutics over...

2014-06-10 16:27:52

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Antibody Partnering Terms and Agreementshttp://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.The Antibody Partnering Terms and...

2014-05-19 08:29:14

PASADENA, Calif., May 19, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates (ADC) using its proprietary monoclonal antibody (mAb) technology platform, today announced the appointment of C. Dan Dumitru, M.D., Ph.D., as Vice President of Translational Research. "We are delighted to expand our highly focused team to include Dan, who brings a strong background in preclinical and translational drug development for biologics...

2014-05-17 23:01:11

ReportsnReports.com offers "Antibody Drug Conjugate Market Opportunity Analysis" report to its research database. The global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. Dallas, Texas (PRWEB) May 17, 2014 Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates...

2014-05-07 04:22:16

OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that it has obtained the exclusive global rights to certain Xenomouse(R) antibodies generated by Amgen and to ImmunoGen's maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related